Dr. Fu has served as Chief Scientific Officer, IGM Infectious Diseases since 2021. Prior to joining IGM he was Head of Vaccine Research, North America, at Sanofi Pasteur, where he led the R&D efforts on multiple vaccine projects, including respiratory syncytial virus, influenza virus, SARS-CoV-2, chlamydia and pertussis, and novel vaccine or technology platforms including mRNA and recombinant human antibodies. Prior to his time at Sanofi, Dr. Fu was a research scientist in vaccines and biologics at Merck & Co., where he contributed to multiple vaccines and biologics programs, and notably, he was the scientific lead for a novel human cytomegalovirus vaccine (V160) which has been advanced to Phase 2 efficacy evaluation. Dr. Fu is also an Adjunct Professor at the Texas Therapeutic Institute, Texas Health Science Center. He received a Ph.D. from the Milton S. Hershey Medical Center at the Pennsylvania State University College of Medicine and an M.D. from Peking University Health Science Center, formerly Beijing Medical University.